Patient out-of-pocket and payer costs for pegfilgrastim originator vs biosimilars as primary prophylaxis of febrile neutropenia in the first cycle among a commercially insured population

BACKGROUND: It is unknown whether using pegfilgrastim biosimilars is cost saving in a real-world setting. OBJECTIVE: To compare medical costs including pegfilgrastim drug costs and febrile neutropenia (FN) treatment and management costs between pegfilgrastim biosimilars (pegfilgrastim-jmdb, pegfilgr...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ching-Yu, Park, Haesuk, Heldermon, Coy D, Vouri, Scott M, Brown, Joshua D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2022
Materias:
Research Brief
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372998/
https://www.ncbi.nlm.nih.gov/pubmed/35737859
http://dx.doi.org/10.18553/jmcp.2022.28.7.795

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372998/
https://www.ncbi.nlm.nih.gov/pubmed/35737859
http://dx.doi.org/10.18553/jmcp.2022.28.7.795

Ejemplares similares